ClinicalTrials.gg
Drug

Sitravatinib clinical trials

Also written MGCD516 and BGB-9468.

studies test it
35
open now
1
in phase 3
5
first study started
2014

How each study uses sitravatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sitravatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sitravatinib
33

Development codes

MGCD516
20
BGB-9468
2
IND 155305
1

Studies by the year they started

35 studies that test it; most in 2021 (10)

Studies that test sitravatinib, by start year
YearStudies
20141
20151
20162
20171
20184
20193
20203
202110
20228
20232

Who runs them

Industry 19 · Other 16

Mirati Therapeutics Inc. (12) · BeiGene (6) · Fudan University (2) · M.D. Anderson Cancer Center (2) · Seoul National University Hospital (1) · Zhejiang Cancer Hospital (1) · BeOne Medicines (1) · Grupo Español Multidisciplinar de Melanoma (1)

Often tested with

Tested in the same studies.

Tislelizumab (12) · Docetaxel (2) · Pamiparib (1) · Hpk1 Inhibitor BGB-15025 (1) · Zanidatamab (1) · AZD4547 (1) · Vistusertib (1) · Palbociclib (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses sitravatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 35

See all 35 studies that test sitravatinib →

Codes

What other systems call sitravatinib · ClinicalTrials.gg INT000552

  • MeSH (NLM) C000611865sitravatinibOne source NLM
  • UNII (FDA) CWG62Q1VTBSITRAVATINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q27275860sitravatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C117734SitravatinibOne source FDA
  • DrugBank DB15036One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.